23 October 2021 (Saturday) - Got the Green Light

I’d not done a BTLP-TACT exercise for a while, so I thought I’d better get busy…

I was presented with one case – a ninety-year old chap in the out-patients department requiring group and save.
He grouped as A Rh(D) Positive with a negative antibody screen

I was rather glad to see I’d got a green light… unlike the red light I got on the last two exercises. I see the messages I sent to the BTLP-TACT people through their Facebook page and Facebook messenger have gone unanswered…

22 October 2021 (Friday) - ASH Update

The nice people at ASH sent the latest developments in treating patients with sickle cells disease. Given the choice I’d rather have had something a little more technical and a little less clinical, but it was useful stuff nonetheless… 

Crizanlizumab Approved for SCD in the U.K. For the first time in 20 years, a new therapy will be made available through the National Health Service via a managed access agreement for the treatment of patients with SCD.

Conserving Red Blood Cell Units in the Treatment of Patients With SCD During Blood Shortages Obtaining pretransfusion hemoglobin S values prior to red cell exchange (RCE) and increasing the RCE end hematocrit above the pretransfusion level led to an 18% reduction in transfused RBC units in patients with SCD who underwent chronic RCE during the COVID-19 pandemic.

Voxelotor Granted Priority Review for Children With SCD Global Blood Therapeutics submitted applications for accelerated approval of voxelotor for the treatment of patients with SCD ages 4 to 11 and for a new dispersible tablet dosage form of the drug.

 

21 October 2021 (Thursday) - Oncologist Update

The nice people at “The Oncologist” sent me their update today. Quite a bit of it went over my head, but one or two snippets stuck. Which is why I subscribe to this newsletter…

	Featured Content Practice-Changing Article Increased Ipsilateral Breast Tumor Recurrence after APBI Brachytherapy for Invasive Lobular Carcinoma In this retrospective review of 946 patients, the authors investigate the effectiveness of accelerated partial breast irradiation for select patients with invasive breast cancer and determined that patients deemed unsuitable for this treatment by criteria established by the American Brachytherapy Society or the American Society for Radiation Oncology were not at increased risk for ipsilateral breast tumor recurrence.			Advertisement

Review Article Immune Checkpoint Inhibitor–Induced Myocarditis Overlap Syndrome This review summarizes the reported cases of immune checkpoint inhibitor–induced myocarditis with myositis and/or myasthenia gravis overlap syndrome (IM3OS).

Advertisement In the News Ludwig Lausanne Study Identifies Potential Combination Therapy for Brain Metastases of Breast Cancer Research Group Uncovers Novel Mechanism that Regulates Breast Cancer Metastases Research Reveals New Understanding of Cancer Resistance to Treatment

Clinical Trial Results

Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial Lessons Learned The combination of anlotinib and S-1 exhibited good antitumor activity in third- or later-line treatment for stage IV non-small cell lung cancer (NSCLC). Combination therapy of anlotinib with S-1 has manageable toxicities in patients with NSCLC.

FUNDING OPPORTUNITY Jose Baselga, MD, PhD, Young Investigator Award in Drug Development

Conquer Cancer, the ASCO Foundation, is soliciting applications for the Jose Baselga, MD, PhD, Young Investigator Award in Drug Development. It’s a one-year $60,000 research grant ($50k to the investigator and $10k to the mentor). For complete eligibility information and application instructions, download the Jose Baselga, MD, PhD, Young Investigator Award in Drug Development RFP. The application deadline is January 10, 2022.

 

Applicants with questions about this award can reach out to Conquer Cancer by email at grants@conquer.org.